BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22002244)

  • 21. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
    Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
    Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
    Wodarz D
    Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
    Albajar M; Gómez-Casares MT; Llorca J; Mauleon I; Vaqué JP; Acosta JC; Bermúdez A; Donato N; Delgado MD; León J
    Mol Cancer Res; 2011 May; 9(5):564-76. PubMed ID: 21460180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
    Bright SA; Campiani G; Deininger MW; Lawler M; Williams DC; Zisterer DM
    Biochem Pharmacol; 2010 Jul; 80(1):31-8. PubMed ID: 20206141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line.
    Tarumoto T; Nagai T; Ohmine K; Miyoshi T; Nakamura M; Kondo T; Mitsugi K; Nakano S; Muroi K; Komatsu N; Ozawa K
    Exp Hematol; 2004 Apr; 32(4):375-81. PubMed ID: 15050748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
    Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
    Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
    Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation.
    Shen Q; Liu S; Chen Y; Yang L; Chen S; Wu X; Li B; Lu Y; Zhu K; Li Y
    J Hematol Oncol; 2013 Sep; 6():64. PubMed ID: 24004697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
    Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
    Mayerhofer M; Aichberger KJ; Florian S; Krauth MT; Hauswirth AW; Derdak S; Sperr WR; Esterbauer H; Wagner O; Marosi C; Pickl WF; Deininger M; Weisberg E; Druker BJ; Griffin JD; Sillaber C; Valent P
    FASEB J; 2005 Jun; 19(8):960-2. PubMed ID: 15784722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
    Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
    Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
    Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
    Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.